OS Therapies OSTX Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect at other companies
Other financials
Where this comes from
Reported directly by OS Therapies in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.
The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about OS Therapies's cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OS Therapies's cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect?
- OS Therapies (OSTX) reported cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect of $647.72K in Q1 2026.
- How has OS Therapies's cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect changed year-over-year?
- OS Therapies's cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect increased by 125.3% year-over-year, from -$2.56M to $647.72K.
- What does cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect mean?
- Represents the net change in the total balance of cash, cash equivalents, and restricted cash over the reporting period, excluding the impact of foreign exchange fluctuations. It serves as a comprehensive measure of the company's overall cash flow health and liquidity movement.